RecruitingPhase 4NCT06558188
Combined Anabolic Therapy
Combined Anabolic Therapy Study
Sponsor
Massachusetts General Hospital
Enrollment
50 participants
Start Date
Feb 3, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Eligibility
Sex: FEMALEMin Age: 45 Years
Inclusion Criteria3
- women aged 45+
- postmenopausal
- osteoporotic with high risk of fracture
Exclusion Criteria9
- no significant previous use of bone health modifying treatments
- known congenital or acquired bone disease other than osteoporosis
- significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
- abnormal calcium or parathyroid hormone level
- serum vitamin D <20 ng/dL
- anemia (hematocrit <32%)
- history of malignancy (except non-melanoma skin carcinoma)
- excessive alcohol use or substance abuse
- known contraindications to romosozumab or teriparatide
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRomosozumab
romosozumab 210 milligrams monthly
DRUGTeriparatide
teriparatide 20 micrograms daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06558188
Related Trials
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
NCT070835571 location
Self-questionnaire in Osteoporosis
NCT070678271 location
U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures
NCT073255783 locations
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
NCT0645508523 locations
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
NCT075465521 location